Ethyreal Bio Launches to Advance Dual-Targeting Thyroid Therapy
Backed by USD 101 million in cumulative financing, Ethyreal Bio is targeting the shared pathogenic driver of Graves' disease and thyroid eye disease with a differentiated, long-acting subcutaneous antibody.
Ethyreal Bio, a biotech company developing precision therapies for thyroid diseases with high unmet need, has launched with financial backing from leading healthcare investors. The emerging biotech has gained USD 101 million through a series of investment rounds, with Series A being co-led by Atlas Venture and Medicxi Ventures, alongside Nandi Life Sciences and Checkpoint Capital, and the Series B including all Series A investors and being led by Avoro Capital (1).
The biotech is developing a promising lead candidate, ETHY-001, aimed at the treatment of Graves’ disease (GD) and thyroid eye disease (TED). ETHY-001 is a monoclonal antibody that works by blocking autoantibody-mediated activation of the thyroid stimulating hormone receptor, which is the shared pathogenic driver of GD and TED.
“GD and TED are prevalent and debilitating conditions with a shared causal driver — pathogenic stimulating autoantibodies to the TSHR,” said Niranjan Kameswaran, Ph.D., Chief Executive Officer of Ethyreal Bio, in a company press release (1). “These two conditions frequently co-exist in the same individual, yet current treatments for GD do not treat or prevent TED, and conversely, TED treatments do not address the hyperthyroidism characteristic of GD. By blocking autoantibody activation of the TSHR, ETHY-001 is designed to target the underlying cause of disease and has the potential to address both conditions through a single, mechanism-driven therapy.”
“Ethyreal has assembled an accomplished management team and seasoned Board of Directors with the scientific, clinical and company-building experience needed to translate compelling biology into transformative medicines,” added Simon Read, Chairman of the Board, in the press release (1). “ETHY-001’s differentiated profile is unique in its potential to address two closely related, debilitating conditions. The Company has made rapid progress and is supported by a healthy capital position. We have strong conviction in Ethyreal’s ability to execute with focus and urgency and to establish itself as the leading company in GD and TED.”
Formulated for low-volume subcutaneous administration, planned via autoinjector, and featuring an incorporated half-life extension technology that will allow for infrequent dosing, ETHY-001 has the potential to offer a patient-centric option to patients with unmet medical needs (1). The company plans to start first-in-human clinical trials during the second half of 2026 and will present data on the therapy at the Endocrine Society’s 2026 Annual Meeting in Chicago on June 15, 2026 (2).
“With our purpose-built team and backing from leading investors, we are focused on rapid, disciplined execution as we advance ETHY‑001 into the clinic in the second half of 2026,” commented Kameswaran in the press release (1). “Our mission is to deliver a therapy that can meaningfully improve outcomes for people living with these burdensome conditions.”
References
Ethyreal Bio. Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease. Press Release, June 10, 2026.
Foster, K. ORF49-07 – ETHY-001, a Half-Life Extended, TSHR Monoclonal Antibody Antagonist, Potently Inhibits TSHR Activation Induced by Patient Sera and M22-Induced Hyaluronan and IL-6 Secretion from TED Patient-Derived Orbital Fibroblasts. Oral Abstract, to be presented at ENDO 2026 in Chicago, Ill., on June 15, 2026.